Type two diabetes and essential hypertension Nutritional, Metabolic, Endocrine Diabetes
Conditions
Interventions
Patients were commenced on captopril 50 mg twice daily and this continued throughout the trial. Patients were randomly assigned to either bendroflumethiazide 1.25 mg once daily or placebo for twelve w
Sponsors
Royal Victoria Hospital (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 40 to 65 years 2. Hypertension (either newly diagnosed or controlled on treatment) 3. Type two diabetes established on dietary treatment with or without oral hypoglycaemic agents 4. Fasting plasma glucose in the range 7 - 12 mmol/l
Exclusion criteria
Exclusion criteria: 1. Secondary hypertension 2. Hepatic or renal disease or were taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or steroids which may affect insulin action
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| When compared to captopril alone, treatment with low dose bendroflumethiaizide (1.25 mg) in combination with captopril produced a 23% reduction in glucose infusion rates required to maintain isoglycaemia and there was a comparable reduction in isotopically induced decline in peripheral insulin sensitivity most probably in skeletal muscle. The combination of low-dose bendroflumethiazide 1.25 mg and captopril resulted in a significant reduction in blood pressure (6/3 mmHg) compared to captopril alone. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum potassium was significantly lower after treatment with captopril and bendroflumethiaizide as compared to treatment with captopril alone. | — |
Countries
United Kingdom
Outcome results
None listed